Lanotan T eye drops solution 2.5 ml. №1

Description

Lanotan Storage
active substances: latanoprost, thymol;

1 ml of the drug contains latanoprost 0.05 mg, timolol maleate in terms of timolol 100% substance 5 mg;

excipients: benzalkonium chloride; sodium dihydrogen phosphate, monohydrate; sodium hydrogen phosphate anhydrous; sodium chloride; water for injections.

Lanotan Dosage form
Eye drops, solution.

Basic physical and chemical properties: transparent colorless liquid.

Lanotan Pharmacotherapeutic group
Antiglaucoma drugs and miotics. Beta-blocking agents. Timolol, combinations. Code ATX S01E D51.

Pharmacological properties

Pharmacodynamics

Lanotan® T contains two active substances: latanoprost and timolol maleate. Both components reduce elevated intraocular pressure through different mechanisms of action, the combined effect leads to a more pronounced decrease in intraocular pressure compared to monotherapy with each of them. Latanoprost, an analogue of prostaglandin F2α, is a selective agonist of prostaglandin FP receptors, which reduces intraocular pressure by increasing the outflow of aqueous humor. The main mechanism of action is to increase uveoscleral outflow. In addition, slightly increased outflow (decreased resistance to outflow in the trabeculae) has been reported in humans. Latanoprost does not significantly affect the production of aqueous humor and the hematopoietic barrier or intraocular blood circulation. Prolonged use of latanoprost in monkeys who underwent extracapsular lens extraction did not affect the retinal vessels according to fluorescent angiography. Latanoprost did not induce fluorescein leakage in the posterior segment of the eye in patients with pseudophakia for a short course of treatment.

Timolol is a blocker (non-selective) of β1- and β2-adrenergic receptors, which has no significant direct sympathomimetic action, direct depressant effect on the myocardium and membrane stabilizing activity. Timolol reduces intraocular pressure by reducing the formation of aqueous humor in the ciliary epithelium. The exact mechanism of action has not been established, but inhibition of enhanced AMP synthesis caused by endogenous stimulation of adrenergic β-receptors is likely.

Timolol does not significantly affect the permeability of the hematopoietic barrier to plasma proteins. In rabbits, timolol did not affect local eye blood flow after prolonged use.

Indication
Decreased intraocular pressure in patients with open-angle glaucoma and increased intraocular pressure with insufficient response to treatment with topical beta-blockers or prostaglandin analogues.

Lanotan Contraindication
Hypersensitivity to the active substance or to any other component of the drug;
reactive diseases of the respiratory tract, including a history of bronchial asthma or bronchial asthma, severe chronic obstructive pulmonary disease;
sinus bradycardia; sinus node weakness syndrome; sinoauricular block; atrioventricular block of the II or III degree which is not subject to control by means of the rhythm driver; clinically pronounced heart failure; cardiogenic shock.